Navigation Links
Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
Date:2/2/2009

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the BIO CEO and Investor Conference on Monday, February 9th, 2009 at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY.

A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, pla
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Outside GC, the leading provider of ... of Debbie Casey as a member of the firm, ... , Debbie has spent over 20 years ... Medical Care North America in both legal and business ... work with Outside GC’s growing list of healthcare clients, ...
(Date:2/27/2015)... and SUMMERLAND, British Columbia , ... XON ), a leader in synthetic biology, ... acquire  Okanagan Specialty Fruits (OSF), the pioneering agricultural ... the world,s first non-browning apple. Through the acquisition, Intrexon ... that is more appetizing and convenient for consumers while ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... Feb. 4 Patients with frequently,relapsing bipolar disorder ... an,initial relapse when risperidone long-acting injection (RLAI) was ... The study compared,patients who received RLAI and standard ... placebo., The study was presented yesterday at ...
... 4 Ardea Biosciences,Inc. (Nasdaq: RDEA ) today ... Advisory Board (SAB) with the,appointment of seven members, chaired ... scientific advice and counsel to the Company regarding,key decisions ... "Establishing a strong scientific advisory board for our ...
... 4 Uroplasty, Inc. (Amex:,UPI) announced today that ... of fiscal 2008 ended December 31, 2007, before ... Company will host a conference call to,discuss these ... a.m. Central,Time. David Kaysen, President and Chief Executive ...
Cached Biology Technology:Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 3Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 4Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 5Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 2Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 3Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 4
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ... 2020. Also, a seven-year historic analysis is provided for these markets. ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... in some living animal groups today has taken on ... evidence shows the feature is at least 100 million ... Munich (Germany), has led an international team of scientists, ... Their research has revealed fossilised evidence for reproduction using ...
... at Oregon State University recently completed the largest animal study ... challenge some basic concepts about how to determine what level ... study found that acceptable levels of at least one carcinogen ... believed. It also indicates that for many purposes trout may ...
... Conservation Society (WCS) announced today a major breakthrough in the ... According to the study, researchers will be able to ... from the unique DNA signature found in their dung. ... samples from tigers that were darted and sedated. The ...
Cached Biology News:Size did matter 2Improved method developed to test carcinogen risk 2Improved method developed to test carcinogen risk 3The straight poop on counting tigers 2
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... The Yeast Protein Kit is a simple ... of yeast cells. The kit has been optimized ... but can be used for any fungus species ... The Zymolyase digestion procedure effectively generates spheroplasts of ...
Biology Products: